We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the ...

Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit ...

Topline results of a Phase II trial reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial ...

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, secures a spot on Fortune's 2025 list of the 100 Most ...

Vertex Pharmaceuticals (VRTX) wrapped up July with a modest 0.16% uptick, signaling a cautious optimism in the stock market.